Safety of artemether-lumefantrine exposure in first trimester of pregnancy: An observational cohort

Malaria Journal

Volumn 13, Issue 1, 2014, Pages

  Mosha, Dominic ^a,b   Mazuguni, Festo ^a   Mrema, Sigilbert ^a   Sevene, Esperanca ^c   Abdulla, Salim ^a   Genton, Blaise ^b,d  

^a IFAKARA HEALTH INSTITUTE   (Tanzania)

^b UNIVERSITY OF BASEL   (Switzerland)

^c EDUARDO MONDLANE UNIVERSITY   (Mozambique)

^d LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Artemether lumefantrine; Exposure; Pregnancy; Safety

Indexed keywords

AMODIAQUINE; ARTEMETHER PLUS BENFLUMETOL; PYRIMETHAMINE PLUS SULFADOXINE; QUININE; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; DRUG COMBINATION; ETHANOLAMINE DERIVATIVE; FLUORENE DERIVATIVE;

ADOLESCENT; ADULT; ARTICLE; CONGENITAL MALFORMATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG SAFETY; FEMALE; FIRST TRIMESTER PREGNANCY; FOLLOW UP; HIGH RISK PREGNANCY; HUMAN; MAJOR CLINICAL STUDY; MALARIA; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PREGNANCY OUTCOME; PREGNANT WOMAN; PREMATURITY; PROSPECTIVE STUDY; SPONTANEOUS ABORTION; STILLBIRTH; TANZANIA; COHORT ANALYSIS; DRUG COMBINATION; MIDDLE AGED; NEWBORN; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIMALARIALS; ARTEMISININS; COHORT STUDIES; DRUG COMBINATIONS; ETHANOLAMINES; FEMALE; FLUORENES; HUMANS; INFANT, NEWBORN; MALARIA; MIDDLE AGED; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREGNANCY OUTCOME; PREGNANCY TRIMESTER, FIRST; PROSPECTIVE STUDIES; QUININE; YOUNG ADULT;

EID: 84901985409     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-13-197     Document Type: Article

References (27)

1. Quantifying the number of pregnancies at risk of malaria in 2007: a demographic study. Dellicour S, Tatem AJ, Guerra CA, Snow RW, ter Kuile FO, PLoS Med 2010 7 1000221 10.1371/journal.pmed.1000221 20126256
2. Epidemiology and burden of malaria in pregnancy. Desai M, ter Kuile FO, Nosten F, McGready R, Asamoa K, Brabin B, Newman RD, Lancet Infect Dis 2007 7 93 104 10.1016/S1473-3099(07)70021-X 17251080 (Pubitemid 46123132)
3. The burden of malaria in pregnancy in malaria-endemic areas. Steketee RW, Nahlen BL, Parise ME, Menendez C, Am J Trop Med Hyg 2001 64 28 35 (Pubitemid 32552569)
4. CfDER, Reviewer guidance evaluating the risks of drug exposure in human pregnancies USA: Food and Drug Administration 2005
5. WHO, Guidelines for the treatment of malaria: second edition Geneva: World Health Organization 2010
6. Sensitive periods for developmental toxicity of orally administered artesunate in the rat. White TE, Clark RL, Birth Defects Res B Dev Reprod Toxicol 2008 83 407 417 10.1002/bdrb.20157 18615704
7. WHO, Assessment of the safety of artemisinin compounds in pregnancy: report of two informal consultations convened in 2006 Geneva: World Health Organization 2007
8. Safety of artemisinins during early pregnancy, assessed in 62 Sudanese women. Adam I, Elhassan EM, Omer EM, Abdulla MA, Mahgoub HM, Adam GK, Ann Trop Med Parasitol 2009 103 205 210 10.1179/136485909X398285 19341535
9. Safety of artemether-lumefantrine in pregnant women with malaria: results of a prospective cohort study in Zambia. Manyando C, Mkandawire R, Puma L, Sinkala M, Mpabalwani E, Njunju E, Gomes M, Ribeiro I, Walter V, Virtanen M, Schlienger R, Cousin M, Chipimo M, Sullivan FM, Malar J 2010 9 249 10.1186/1475-2875-9-249 20809964
10. Novartis Malaria Initiative: best practice example of pharmaceutical industry's engagement in the fight against malaria. Lefevre G, Marrast AC, Grueninger H, Ann N Y Acad Sci 2011 1222 19 29 10.1111/j.1749-6632.2011.05973.x 21434939
11. Ministry of Health of Tanzania, National guideline for malaria diagnosis and treatment 2005 Tanzania: National Malaria Control Programme 2006
12. Increasing access to medicines in Tanzania. Mbwasi R, Mlaki W, Lancet 2008 372 205 206 (Pubitemid 351978106)
13. Increasing access to subsidized artemisinin-based combination therapy through accredited drug dispensing outlets in Tanzania. Rutta E, Kibassa B, McKinnon B, Liana J, Mbwasi R, Mlaki W, Embrey M, Gabra M, Shekalaghe E, Kimatta S, Sillo H, Health Res Policy Syst 2011 9 22 10.1186/1478-4505-9-22 21658259
14. Treatment seeking for malaria: a review of recent research. McCombie SC, Soc Sci Med 1996 43 933 945 10.1016/0277-9536(95)00446-7 8888463 (Pubitemid 26306536)
15. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Dondorp AM, Fanello CI, Hendriksen IC, Gomes E, Seni A, Chhaganlal KD, Bojang K, Olaosebikan R, Anunobi N, Maitland K, Kivaya E, Agbenyega T, Nguah SB, Evans J, Gesase S, Kahabuka C, Mtove G, Nadjm B, Deen J, Mwanga-Amumpaire J, Nansumba M, Karema C, Umulisa N, Uwimana A, Mokuolu OA, Adedoyin OT, Johnson WB, Tshefu AK, Onyamboko MA, Sakulthaew T, Ngum WP, Silamut K, Stepniewska K, Woodrow CJ, Bethell D, Wills B, Oneko M, Peto TE, von Seidlein L, Day NP, White NJ, Aquamat group, Lancet 2010 376 1647 1657 10.1016/S0140-6736(10)61924-1 21062666
16. Efficacy and safety of artemether-lumefantrine compared with quinine in pregnant women with uncomplicated Plasmodium falciparum malaria: an open-label, randomised, non-inferiority trial. Piola P, Nabasumba C, Turyakira E, Dhorda M, Lindegardh N, Nyehangane D, Snounou G, Ashley EA, McGready R, Nosten F, Guerin PJ, Lancet Infect Dis 2010 10 762 769 10.1016/S1473-3099(10)70202-4 20932805
17. Update on genetic markers of quinine resistance in Plasmodium falciparum. Okombo J, Ohuma E, Picot S, Nzila A, Mol Biochem Parasitol 2011 177 77 82 10.1016/j.molbiopara.2011.01.012 21295079
18. Longitudinal in vitro surveillance of Plasmodium falciparum sensitivity to common anti-malarials in Thailand between 1994 and 2010. Parker D, Lerdprom R, Srisatjarak W, Yan G, Sattabongkot J, Wood J, Sirichaisinthop J, Cui L, Malar J 2012 11 290 10.1186/1475-2875-11-290 22908880
19. Preliminary results of the 2011-12 Tanzania HIV/Aida and malaria indicator survey (THMIS). Statistics TNBo, NBS 2012 24 27
20. Incidence and outcome of bleeding before the 20th week of pregnancy: prospective study from general practice. Everett C, BMJ 1997 315 32 34 10.1136/bmj.315.7099.32 9233324 (Pubitemid 27271683)
21. Deficient supplies of drugs for life threatening diseases in an African community. Lufesi NN, Andrew M, Aursnes I, BMC Health Serv Res 2007 7 86 10.1186/1472-6963-7-86 17573958 (Pubitemid 47030152)
22. Stock out or in stock? Acess to medicines in Tanzania. Twaweza, Twaweza 2013 5 1 4
23. The use of quinine during pregnancy, labour, and the puerperium. Maxwell JP, Trans R Soc Trop Med Hyg 1908 1 229 235
24. WHO, Congenital anomalies Geneva: World Health Organization 2012
25. Crossed polydactyly type I caused by a point mutation in the GLI3 gene in a large Chinese pedigree. Cheng B, Dong Y, He L, Tang W, Yu H, Lu J, Xu L, Zheng B, Li K, Xiao C, J Clin Lab Anal 2006 20 133 138 10.1002/jcla.20121 16874813 (Pubitemid 44188303)
26. The prevalence, spontaneous resolution, and parent's attitudes towards umbilical hernia coexisting in Nigerian children presenting with other surgical pathology. David O, David M, Ann Pediatr Surg 2009 5 16 20
27. Incidence of umbilical hernia in African children: redefinition of "normal" and reevaluation of indications for repair. Meier DE, OlaOlorun DA, Omodele RA, Nkor SK, Tarpley JL, World J Surg 2001 25 645 648 10.1007/s002680020072 11369993 (Pubitemid 32441440)